




CHIMERIC

PIONEERS IN CELL THERAPY

Clinical Trial Update 2025





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements

contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



INVESTMENT HIGHLIGHTS

4

4 Phase 1 clinical trials
under 3 FDA INDs at 4 leading US centres



Multiple clinical updates
in the next 12mths



Experienced leadership team
in cell therapy clinical development



CHM-CDH17
the FIRST CDH17 CAR-T in clinical trials



First in class
CLTX-CAR for brain cancer



Robust and long life
patent portfolio

CORPORATE PROFILE

Exchange **ASX: CHM**

Share Price **\$0.003**

52 Week Range **\$0.002 - 0.017**

Market Cap **~ 10m**

Shares on issue **~3.2B**

IPO 2021



CHM LEADERSHIP TEAM

EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION



 Dr Rebecca McQUALTER
Chief Executive Officer



 Dr Jason LITTEN
Chief Medical Officer



 Dr Stephanie ASTROW
Chief Scientific Officer

EXPERIENCE

50+ Years of Cell Therapy Experience

EXPERTISE

50+ Development Programs

RESULTS

5/7 FDA-Approved CAR T Cell Therapies

AMGEN

juno
THERAPEUTICS

Celgene

Kite

YESCARTA

TECARTUS

NOVARTIS

Fcete
THERAPEUTICS

artiva

KYMRIAH[®]
(tisagenlecleucel)
Suspension for IV infusion

Abecma

Breyanzi



CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17 CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

4 sites active

CHM CORE-NK 'OFF THE SHELF' NK

Technology from:



PHASE 1B
TRIAL OPEN

MD Anderson

PHASE 1B
TRIAL OPEN

Case Western

CHM CLTX

Technology from:



Phase 1A completed: COH

PHASE 1B TRIAL


1 site active



CHM CDH17

Clinical Trial Update

October 2025





CDH17 OVERVIEW



Over a decade of development at the world-renowned cell therapy centre, The University of Pennsylvania



Compelling pre-clinical efficacy in gastric, pancreatic and neuroendocrine Cancers




Pre-clinical models indicate no toxicity in healthy cells



This is the first CDH17 CAR-T Cell Therapy in clinical trials in the world




CDH17 is protein on the surface of Gastrointestinal cancers (green on purple cell in picture)



Dr. Xianxin Hua,
M.D., Ph.D.




Dr. Carl June M.D.






ENCOURAGING PRE-CLINICAL RESULTS


CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models




NEUROENDOCRINE TUMOURS



GASTRIC CANCER



PANCREATIC CANCER



CHM CDH17
CAR-T



Source: Feng et al., Nature Cancer, 2022



CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials globally

CHM CDH17
CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

4 sites actively recruiting

PERSONALISED CAR-T: AUTOLOGOUS

4 prestigious sites recruiting: Sarah Cannon, UPenn, Uchiacgo, Emory

FDA IND clearance: Nov 23

FDA FASTRACK GRANTED

Manufacturing: 10/10 successful runs; GMP Compliant

Phase 1/2 Trial Open in Colorectal, Gastric and Neuroendocrine Cancers


10 Patients enrolled:

8 Patients treated, 2 awaiting dosing assignment

N= up to 15 patients



Phase 1/2 Clinical Trial of CHM CDH17 Design



[NCT06501183](https://clinicaltrials.gov/ct2/show/study/NCT06501183)



CHM CDH17 PROGRESS AS AT OCT 8TH, 2025

Dose Level	Status	Notes
1 50m	Completed	4 patients treated 1 patient remains on study
2 150m	Recruitment Ongoing	4 patients treated
3 450m	Recruitment underway	2 patients awaiting dosing assignment
Manufacturing	GMP compliant	10 out of 10 successful runs



CLINICAL PRELIMINARY RESULTS

DOSE LEVEL 1 COMPLETED

50m Cells	Tumour Type	Status
Patient 1	CRC	No follow up
Patient 2	NET	Stable Disease until day 150 progression Grade 1 CRS
Patient 3	CRC	Stable Disease at day 300.
Patient 4	CRC	Progressive Disease at day 28

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumor (Intestinal NET)



CLINICAL PRELIMINARY RESULTS

DOSE LEVEL 2 Ongoing

150m Cells	Tumour Type	Status
Patient 5	CRC	Stable Disease 90days Tumour Shrinkage 12%
Patient 6	NET	Stable Disease Tumour Shrinkage 6%-37%
Patient 7	CRC	Treated.
Patient 8	CRC	Treated.

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumor (Intestinal NET)



CHM CDH17 PROGRESS

RECRUITMENT UNDERWAY


TBD Dose of Cells	Tumour Type	Status
Patient 9	NET	Manufactured. Dose yet to be assigned
Patient 10	NET	Manufactured. Dose yet to be assigned
TBD		
TBD		

CRC= Colorectal Cancer (Bowel Cancer)

NET= NeuroEndocrine Tumor (Intestinal NET)




CHM CDH17 CAR-T cells expand and persist





TOTAL GLOBAL MARKET SIZE





SUMMARY + FY26 CATALYSTS

●●
CHM CDH17
CHM 2101

8 patients treated
10/10 manufacturing runs
Anti-tumour activity observed
No safety issues to date
No off-target effects

FY26 Deliverables


Complete Dose level 2
Commence Dose level 3 (if appropriate)
Conclude Phase 1
Phase 2 readiness



CHM CORE NK

Clinical Trial Update

October 2025





CHM CORE-NK 2 PHASE 1B TRIALS OPEN

Phase 1b clinical trials OPEN

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:

 **CASE
WESTERN
RESERVE**
UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

OFF THE SHELF: ALLOGENEIC

NK cell expansion platform: **Universal Donor**

Positive Phase 1A Clinical Trial in AML

Two ongoing Phase 1B Clinical Trials in AML + CRC

MDACC AML: **Cohort 1 cleared, moved to dose expansion for Cohort 2 FRONTLINE - A FIRST IN CELL THERAPY**

1 Patient dosed; rapidly recruiting

Case Western AML + CRC: 4 patients dosed

Foundation for asset development




AML PHASE 1B CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in FRONTLINE AML

Clinical Trials.gov Identifier: NCT05834244

THE UNIVERSITY OF TEXAS
MDAnderson
~~Cancer~~ Center



CORE NK CELLS



FDA REGISTERED
CHEMOTHERAPY




FDA REGISTERED
BLOOD CANCER DRUG

○●
CHM CORE NK
'OFF THE SHELF' NK



CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Four Completes Responses, 1 Partial Response



Complete Response means that all visible or measurable signs of cancer have disappeared after treatment

Partial Response means the cancer has reduced by at least 50% but not entirely disappeared in response to treatment



SUMMARY CHM CORE-NK

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation competed

First Line Dosing Underway – up to 20 patients

No safety issues to date

FY26 Deliverables

Complete dosing of 20 patients; subject to MD Anderson



SUMMARY

CHM CDH17

CHM 2101

8 patients treated

10/10 manufacturing runs

Tumour shrinkage observed

10

No safety issues to date

No off-target effects

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation completed

First Line Dosing Underway – 7 dosed up to 20 patients

No safety issues to date



CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com

